Trial Profile
A Study to Evaluate the Impact of Omalizumab on Symptoms and Exacerbations in COPD Patients With Atopic Phenotype
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 28 Jun 2016 New trial record
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society